注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Olema Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于女性癌症靶向疗法的发现、开发和商业化。其主要候选产品OP-1250是一种口服疗法,具有完全雌激素受体(ER)拮抗剂(CERAN)和选择性ER降解剂(SERD)的联合活性。OP-1250是治疗内分泌驱动型癌症的口服小分子临床阶段候选产品。它的设计基于对ER的结构理解。OP-1250作为一种单一疗法,并与细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂联合使用,在几种异种移植模型(包括乳腺癌脑转移模型)中显示出强烈的肿瘤收缩。这是在转移性ER阳性(ER+)、人表皮生长因子受体2阴性(HER2-)乳腺癌患者中进行的I期/II期临床试验,以及与palbociclib联合进行的I期临床试验。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Gorjan Hrustanovic | 35 | 2018 | Independent Director |
Frank P. McCormick | 74 | 2014 | Chairman of Scientific Advisory Board |
Sandra J. Horning | 75 | 2020 | Independent Director |
Sean W. Fanning | - | - | Member of Scientific Advisory Board |
Mark Sliwkowski | - | - | Member of Scientific Advisory Board |
Christopher C. Benz | - | - | Member of Scientific Advisory Board |
Cynthia Marie Butitta | 70 | 2020 | Independent Director |
Yi Larson | 43 | 2021 | Independent Director |
Pamela M. Klein | 63 | 2020 | Member of Scientific Advisory Board |
Cyrus L. Harmon | 53 | 2006 | Director |
Andrew S. Rappaport | 65 | 2013 | Independent Director |
Sean P. Bohen | 57 | 2020 | President, CEO & Director |
Graham Gordon Walmsley | 37 | 2020 | Independent Director |
Ian T. Clark | 64 | 2020 | Independent Chairperson of the Board |
Pamela Munster | - | - | Member of Scientific Advisory Board |
Jeffrey Hager | 59 | - | Member of Scientific Advisory Board |
Geoffrey Greene | - | - | Member of Scientific Advisory Board |
Scott Garland | 55 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核